News

Dr. Baaziz Achour Takes Charge as Qualcomm's New CTO

Dr. Baaziz Achour Takes Charge as Qualcomm's New CTO

Dr. Baaziz Achour Appointed Chief Technology Officer at Qualcomm

Qualcomm Incorporated (NASDAQ: QCOM) is thrilled to announce the advancement of Dr. Baaziz Achour to Chief Technology Officer at Qualcomm Technologies, Inc. This exciting appointment comes alongside the retirement of Dr. James Thompson, marking a significant transition in Qualcomm's leadership team. Dr. Achour, who has been diligently serving as Deputy Chief Technology Officer, assumes this pivotal role, which underscores Qualcomm's strategic vision for future technological advancements.

Key Responsibilities and Strategic Vision

In his new capacity as CTO, Dr. Achour will spearhead Qualcomm’s research and development initiatives and oversee the engineering organizations. His mission will be to guide technology strategy, ensuring Qualcomm continues to lead in critical areas such as wireless communications, computing, and artificial intelligence (AI). Cristiano Amon, President and CEO of Qualcomm Incorporated, expressed enthusiasm for collaborating with Dr. Achour in propelling the company’s innovative journey forward.

Recognizing Dr. James Thompson's Legacy

Amon also took a moment to recognize the immense contributions of Dr. Thompson during his 33-year tenure with Qualcomm. His leadership in advancing wireless technology has formulated one of the industry's most comprehensive technology portfolios. This portfolio has been crucial in not only maintaining Qualcomm’s dominance in the mobile sector but also expanding its ventures into markets like Automotive, PC, Industrial applications, XR, and networking.

Dr. Achour's Career Journey

Dr. Achour's journey with Qualcomm began in 1993, marking nearly three decades of impressive growth and innovation. Starting as a Systems Engineer, he ascended through various leadership roles within the engineering division. Dr. Achour's expertise has been influential in the development of nearly every generation of wireless technology, establishing him as a key figure in the rapid deployment of 5G technology. Additionally, he will spearhead Qualcomm's ambitious evolution towards 6G cellular technology.

Education and Patent Contributions

Dr. Achour's academic credentials are equally impressive; he holds a B.S. in Physics from the University of Algiers, complemented by master’s and doctoral degrees in Electrical Engineering from Tufts University. Furthermore, he is an inventor on twenty-four granted U.S. patents in the field of wireless communications, showcasing his commitment to innovation and technology advancement.

About Qualcomm

Qualcomm is at the forefront of relentless innovation, focused on delivering intelligent computing solutions that address pressing global challenges. Its transformative technologies are instrumental across numerous industries, with its Snapdragon branded platforms creating extraordinary experiences for consumers. With a robust legacy of nearly four decades in establishing industry standards and groundbreaking technology, Qualcomm continues to lead in AI, high-performance computing, and unbeatable connectivity.

As part of Qualcomm Incorporated, the company encompasses its licensing business, QTL, and holds one of the most extensive patent portfolios available. Qualcomm Technologies, Inc. operates primarily in engineering and research and development, along with providing an array of products and services that include the QCT semiconductor business. The Qualcomm and Snapdragon brands are integral to this innovative ecosystem.

Frequently Asked Questions

Who has been appointed as Qualcomm's new Chief Technology Officer?

Dr. Baaziz Achour has been appointed as the new Chief Technology Officer of Qualcomm Technologies, Inc.

What role will Dr. Achour play at Qualcomm?

Dr. Achour will lead Qualcomm’s research and development, focusing on technology strategy, wireless communications, computing, and AI.

What is the significance of Dr. Thompson's retirement?

Dr. Thompson's retirement marks the end of a significant era at Qualcomm, where he contributed to the growth of extensive technology portfolios, significantly impacting the industry.

What educational background does Dr. Achour have?

Dr. Achour holds a B.S. in Physics from the University of Algiers and both master’s and doctorate degrees in Electrical Engineering from Tufts University.

What are Qualcomm's main business areas?

Qualcomm's main business areas include mobile technology, AI, computing, licensing, and semiconductor products across various industries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Kinetic Seas Incorporated Secures First Customer Success

Updated Category News Views 56

Kinetic Seas Incorporated Secures First Customer and Financial Growth Kinetic Seas Incorporated (OTC: ECGR) is excited to announce the signing of its first customer, along with impressive revenue results for the second quarter. This milestone marks a significant step forward as the company pursues its goals in the artificial intelligence sector. Second Quarter Revenue...

Continue Reading
Webinar Guide for Veterans to Maximize Benefits Offered by CCK Law

Updated Category News Views 134

Helping Veterans Discover VA Benefits with a Free Webinar Chisholm Chisholm & Kilpatrick LTD (CCK Law), a preeminent veterans disability law firm, is excited to introduce a free, on-demand webinar aimed at assisting veterans in uncovering valuable VA benefits that many may be unaware of. Insights from the Experts The webinar, dubbed "Biggest Benefits Veterans Overlook,"...

Continue Reading
Tech Market Shifts: Navigating Opportunities and Challenges Ahead

Updated Category News Views 161

Understanding Recent Market Dynamics In recent weeks, global markets have been experiencing heightened volatility, particularly in the technology sector. With various significant events unfolding—including new political leadership in Japan and shifts in economic data—investors are carefully analyzing these developments to navigate potential risks and opportunities....

Continue Reading
Michael Beland Joins Advance Auto Parts as Chief Accounting Officer

Updated Category News Views 720

Welcome Michael Beland to Advance Auto Parts Advance Auto Parts, Inc. (NYSE: AAP), known for its significant role in the automotive aftermarket, recently made an important announcement regarding its executive leadership. The company has appointed Michael Beland as the new senior vice president, controller, and chief accounting officer, marking a pivotal addition to their...

Continue Reading
Recall Movement Against Governor Newsom Gains Momentum

Updated Category News Views 276

Recall Movement Gains Traction in California In an unprecedented move, SavingCalifornia.vote has taken a significant step to initiate a recall against Governor Gavin Newsom. This initiative marks a pivotal moment in California's political landscape. The organization is gathering support and will soon submit the official notice of intent to recall, alongside the necessary...

Continue Reading